This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

7 Jun 2011

J&J to Pay $327M in Risperdal Case

Johnson & Johnson unit Ortho-McNeil-Janssen Pharmaceuticals has been ordered to pay more than $327m in a case regarding its marketing of the antipsychotic Risperdal.

Civil penalties amounting to over $327m have been announced in the groundbreaking case between the US state of South Carolina vs Ortho-McNeil-Janssen Pharmaceuticals, a unit of Johnson & Johnson.


The case focuses upon violations found with drug labels and "dear doctor" letters that actively marketed the antipsychotic drug Risperdal in a deceptive manner, claiming that the drug was safer and better than competing medicines.


Circuit Court judge Roger Couch ruled that more than 500,000 package inserts were distributed with sample boxes and levied a $300 charge per violation, adding to a $4,000 charge per violation regarding "dear doctor" letters, of which there were in excess of 43,000.


Related News